← Back to Search

Monoclonal Antibodies

Individuals with moderate-to-severe psoriasis for Plaque Psoriasis

Q: Is the recruitment for this study still ongoing at present?

According to details on clinicaltrials.gov, this investigation is actively pursuing volunteers. It was initially made public on March 1st, 2024 and received its most recent update on March 21st, 2024.

Q: What is the overall count of individuals participating in this clinical study?

Indeed, as per clinicaltrials.gov data, this trial is actively seeking participants. Initially listed on March 1st, 2024 and most recently revised on March 21st, 2024, the study aims to recruit a total of 60 individuals from two distinct sites.

Q: What level of risk do individuals with moderate-to-severe psoriasis pose to others?

Our team at Power rates the safety of individuals with moderate-to-severe <a href="https://www.withpower.com/clinical-trials/psoriasis">psoriasis</a> as a 3 on our scale. This rating is influenced by the fact that this trial falls under Phase 4, indicating approval for this treatment approach.

Phase 4

Recruiting

Led By Mark Lebwohl, MD

Research Sponsored by Icahn School of Medicine at Mount Sinai

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, week 4, week 8, week 12, week 16

Awards & highlights

Study Summary

This trial aims to test a new medication called bimekizumab for treating moderate-to-severe psoriasis in patients who have not responded well to other treatments. Bimekizumab

Who is the study for?

This trial is for individuals with moderate-to-severe plaque psoriasis who haven't had success with therapies targeting interleukin IL-17A or 23. Participants should have a history of treatment failure and be in need of an alternative.Check my eligibility

What is being tested?

The study tests bimekizumab's effectiveness and safety in treating psoriasis. Bimekizumab works by blocking substances called interleukins (IL-17A and IL-17F) to reduce inflammation associated with the condition.See study design

What are the potential side effects?

Potential side effects may include reactions at the injection site, infections due to lowered immune response, headaches, fatigue, and possible gastrointestinal issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, week 4, week 8, week 12, week 16

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, week 4, week 8, week 12, week 16

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 4, week 8, week 12, week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Body Surface Area (BSA) of < 1

Secondary outcome measures

Physician Global Assessment (PGA) of < 1

Physician Global Assessment (PGA) of < 2

Psoriasis and Severity Index Score (PASI) of < 1

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Individuals with moderate-to-severe psoriasisExperimental Treatment1 Intervention

Individuals with moderate-to-severe psoriasis who have failed similar therapies.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bimekizumab

2018

Completed Phase 3

~6510

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

UCB PharmaIndustry Sponsor

341 Previous Clinical Trials

109,259 Total Patients Enrolled

Psoriasis Treatment Center of Central New JerseyOTHER

14 Previous Clinical Trials

382 Total Patients Enrolled

Icahn School of Medicine at Mount SinaiLead Sponsor

862 Previous Clinical Trials

525,566 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment for this study still ongoing at present?

"According to details on clinicaltrials.gov, this investigation is actively pursuing volunteers. It was initially made public on March 1st, 2024 and received its most recent update on March 21st, 2024."

Answered by AI

What is the overall count of individuals participating in this clinical study?

"Indeed, as per clinicaltrials.gov data, this trial is actively seeking participants. Initially listed on March 1st, 2024 and most recently revised on March 21st, 2024, the study aims to recruit a total of 60 individuals from two distinct sites."

Answered by AI

What level of risk do individuals with moderate-to-severe psoriasis pose to others?

"Our team at Power rates the safety of individuals with moderate-to-severe psoriasis as a 3 on our scale. This rating is influenced by the fact that this trial falls under Phase 4, indicating approval for this treatment approach."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Bimekizumab in Plaque Psoriasis

Mark Lebwohl 2024. "Bimekizumab in Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06336343.

All > Psoriasis > Plaque Psoriasis